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Drs Lowe and Khachigian suggest that the coating of stents with drugs including sirolimus is a "blunderbuss" approach, whereas the use of a DNAzyme such as one they are studying that cleaves Egr-1 mRNA is the "magic bullet," with "potentially greater specificity, decreased toxicity and with fewer side effects." Elsewhere Drs Lowe and colleagues 1 refer to the target of their "magic bullet" as follows: "Early growth response factor-1 (Egr-1) controls the expression of a growing number of genes involved in the pathogenesis of atherosclerosis and postangioplasty restenosis. Egr-1 is activated by diverse proatherogenic stimuli." It is not clear how targeting a transcription factor that controls "a growing number of genes" and is activated by "diverse" stimuli is more specific than rapamycin.
Over the past decade, many of the details regarding the molecular mechanisms underlying rapamycin's actions have been elucidated, and these basic investigations are ongoing. 2,3 At the same time, it is important to note that rapamycin has been approved by the FDA for long-term systemic administration as an immunosuppressant, indicating a degree of safety not yet demonstrated in humans for Egr-1 targeting by DNAzymes. Interestingly, Egr-1 deficient mice have been reported to be hyperresponsive to stress and infertile. 4, 5 Findings such as these suggest that a "magic bullet" targeted at Egr-1 could itself have unfortunate side effects and requires extensive in vivo testing before it is administered to patients.
